Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) represents the hepatic manifestation of the Metabolic Syndrome and is emerging as a key driver of morbidity and mortality, particularly when present in the context of severe liver fibrosis. The histological hallmarks of NASH including steatosis, lobular inflammation and hepatocyte ballooning are well-characterized, however while it is widely recognized that NASH is a progressive disease, the pathogenic and molecular mechanism/s that initiate and drive NASH remain largely unknown. The primary purpose of this meeting is to bring together a broad group of scientific and clinical researchers to highlight and discuss the current evidence exploring the key biological processes involved in NASH and liver fibrosis. Insulin resistance, hepatocyte lipid management/lipotoxicity and inflammation in the context of steatosis and NASH will be reviewed. Advances in our understanding of the molecular and genetic regulation of NAFLD/NASH and the progression to liver fibrosis will also be highlighted. Finally, as NASH is an unmet medical need, we will integrate the earlier fundamental biology discussion with updates on clinical progress of therapeutic agents, and combinations of agents, for the treatment of NASH and liver fibrosis. The parallel joint meeting with one focused on key cellular drivers and mediators of fibrosis in organs beyond the liver allows for cross-functional discussion and deeper understanding of pathobiology of fibrotic disease.